Icosavax Announces Topline Interim Phase 1/2 Results For IVX-411 Against SARS-CoV-2
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP technology; end-to-end drug